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GALEOTTI, N., C. GHELARDINI AND A. BARTOLINI. Piracetam and aniracetam antagonism of centrally active 
drug-induced antinociception. PHARMACOL BIOCHEM BEHAV 53(4) 943-950, 1996. -The effects of the nootropic 
drugs piracetam and aniracetam on antinociception induced by baclofen, bicuculline, and picrotoxin and on baclofen-induced 
muscle relaxation were studied in mice. Antinociception was investigated using both the hot plate (thermal stimulus) and 
abdominal constriction (chemical stimulus) tests. Both behaviour inhibition and muscle relaxation were observed by using the 
rota-rod test. Piracetam (30 mg/kg, IP) and aniracetam (10 mg/kg, PO) reduced baclofen, bicuculline, and picrotoxin 
antinociception without modifying analgesia induced by non-GABAergic drugs such as morphine, physostigmine, clomipram- 
ine, and diphenhydramine. In this concentration range, piracetam, and aniracetam were also able to reduce the inhibition of 
rota-rod performance. At higher doses piracetam (100 mg/kg, IP) and aniracetam (100 mg/kg, PO) were able to completely 
prevent baclofen antinociception. However, when prevention of GABAergic antinociception was complete, piracetam and 
aniracetam were able to block non-GABAergic antinociception also. Comparing the effects of piracetam and aniracetam with 
those exerted by the GABAa antagonist CGP 35348, a reduction of non-GABAergic analgesia was also observed using higher 
doses of CGP 35348 (2.5 pg per mouse ICV). The present results indicate that piracetam and aniracetam, by preventing both 
of the investigated effects of baclofen, have some selectivity against GABA,-mediated inhibition. The well-known activity of 
piracetam and aniracetam on learning and memory might, therefore, depend, at least in part, on the removal of inhibitory 
GABAt, mechanisms that impair attention and cognitive functions. 
Learning and memory Nootropic 
Analgesia Antinociception 
Piracetam Aniracetam CGP 35348 GABA GABA, receptor 
NOOTROPICS (noos = mind, tropein = towards) represent 
a heterogeneous compound group that facilitates learning and 
memory or overcomes natural or induced cognitive impair- 
ments in laboratory animals (10,23). Nevertheless, results 
from controlled clinical trials have questioned the usefulness 
of nootropic compounds for treatment of cognitive disorder 
in humans (31). They typically have low toxicity, no sedative 
or stimulatory effects, and variously affect flow and metabo- 
lism in the brain (13). The nootropic drugs include the 2- 
pyrrolidinone derivatives piracetam, oxiracetam, pramira- 
cetam, etiracetam, aniracetam, rolziracetam, and tenilsetam 
(23). Although no commonly accepted mechanism of action 
has been established (lo), it has been shown that these com- 
pounds facilitate the transcallosal, interhemispheric transfer 
of information (25) and enhance long-term potentiation (LTP) 
in guinea pig hippocampal slices (28,32). Piracetam might al- 
ter presynaptic cholinergic functions, possibly by enhancing 
high-affinity neuronal uptake of choline (26,36), but these 
data are still a matter of controversy (8,34). Pilch and Mtiller 
’ To whom requests for reprints should be addressed. 
showed that piracetam elevated muscarinic receptor density in 
the frontal cortex of aged but not of young mice (27). Anira- 
cetam was found to be able to increase the acetylcholine con- 
tent in the hippocampus but not in the corpus striatum (35). 
The possible involvement of steroids in the piracetam-like 
nootropics mechanism of action has also been examined 
(19,20). Copani et al. reported that piracetam, aniracetam, 
and oxiracetam may act as positive modulators of AMPA- 
sensitive glutamate receptors in neurons (5). 
The numerous mechanisms so far suggested to explain the 
nootropic effect of the 2-pyrrolidinone compounds are a clear 
indication that the exact mechanism of action of these drugs is 
still unknown. 
Recently, Mondadori et al. (21), Carletti et al. (4), and 
Bianchi and Panerai (2) reported that the GABA, receptor 
antagonists CGP 36742 and CGP 35348 are able to ameliorate 
cognitive processes including memory and learning in mice, 
rats, and rhesus monkeys. Numerous hormonal, behavioural, 
and cellular effects have been attributed to the activation of 
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GABA, receptors (3). Baclofen, a GABA, agonist, is able, for 
instance, to impair learning and memory (33) and to induce 
antinociception and muscle relaxation (7,16). Malcangio et al. 
(17,18) have shown that, by blocking GABA, receptors with 
the selective antagonist CGP 35348 (24), it is possible to pre- 
vent the analgesic effect consequent to direct (baclofen) and 
indirect (bicuculline and picrotoxin) GABA, activation. Fur- 
thermore, CGP 35348 was also able to antagonize the motor 
incoordination consequent to the muscle-relaxant effect of 
baclofen (17,24). 
Because the effects of GABA, antagonists (CGP 36742 and 
CGP 35348) on ameliorating learning and memory and on 
preventing antinociception could be attributed to the removal 
of the GABAergic tonic inhibition, we considered it worth- 
while to investigate whether the 2-pyrrolidinone compounds 
could act through the same mechanism. This hypothesis was 
also supported by the structural similarity between the GABA 
moiety and the moieties of the 2-pyrrolidinone compounds 
that are all cyclic derivatives of GABA itself (Fig. 1). To this 
end, because the GABA, antagonist CGP 35348 was not only 
able to improve learning and memory but also to prevent 
baclofen-induced antinociception and muscle relaxation, ef- 
fects of piracetam and aniracetam on analgesia produced by 
baclofen, bicuculline, and picrotoxin in the mouse hot plate 
and abdominal constriction tests were examined. Effects of 
piracetam and aniracetam on baclofen-induced impairment of 
rota-rod performance in mice were also investigated. Mor- 
phine, physostigmine (12), clomipramine (30), and diphenhy- 
dramine (29) were used as non-GABAergic reference drugs. 
METHODS 
Animals 
Male Swiss albino mice (23-30 g) were used. Fifteen mice 
were housed per cage. The cages were placed into the experimen- 
tal room 24 h before the test for acclimatization. The animals 
were fed a standard laboratory diet and tap water ad lib. 
Hot Plate Test 
Mice were placed inside a stainless container, thermostati- 
cally set at 52.5 + O.l°C in a precision water bath from CW 
Mechanical Workshop (Siena, Italy). Reaction times (sec- 
onds), were measured with a stopwatch and each animal was 
tested before and 15, 30, 45, and 60 min after treatment. The 
endpoint used was the licking of the fore or hind paws. Those 
mice scoring below 12 and over 18 s in the pretest were re- 
jected. An arbitrary cutoff time of 45 s was adopted. 
FIG. 1. GABA, piracetam, and aniracteam chemical structure. 
Abdominal Constriction Test 
Mice were injected IP with a 0.6% solution of acetic acid 
(10 ml/kg). The number of stretching movements was counted 
for 10 min, starting 5 min after acetic acid injection. 
Rota-Rod Test 
The apparatus consisted of a base platform and a rotating 
rod of 3 cm diameter with a nonslippery surface. This rod was 
placed at height of 15 cm from the base. The rod, 30 cm in 
length, was divided into five equal sections by six disks. Thus, 
up to five mice were tested simultaneously on the apparatus, 
with a rod-rotating speed of 16 rpm. The integrity of motor 
coordination was assessed on the basis of endurance time of 
the animals on the rotating rod. One day before the test, the 
animals were trained twice. On the day of the test only the 
mice that were able to stay balanced on the rotating rod be- 
tween 70 and 120 s (cutoff time) were selected for testing. The 
performance time was measured before and at various times 
after treatment. 
Drugs 
The following drugs were used: (k)-baclofen (/3-p- 
chlorophenyl GABA), picrotoxin, (+)-bicuculline, physo- 
stigmine hemisulphate, piracetam (Sigma), morphine hydro- 
cloride (U.S.L. 10/D, Florence), aniracetam (A. Menarini 
lndustrie Farmaceutiche Riunite S.r.l.), CGP 35348 (3- 
aminopropyl-diethoxymethyl-phosphinic acid, Ciba-Geigy), 
clomipramine hydrocloride (anafranil, Ciba-Geigy), and di- 
phenhydramine hydrocloride (De Angeli). 
All drugs were dissolved in isotonic (NaCl 0.9%) saline 
solution immediately before use, except aniracetam, which 
was dispersed in sodium carboxymethyl cellulose 1%. Solu- 
tions of bicuculline were prepared immediately before the ex- 
periments by dissolving 10 mg of bicuculline base in 400 ~1 
HCl(O.1 N) and then adding saline up to 10 ml. Drug concen- 
trations were prepared in such a way that the necessary dose 
could be administered in a volume of 10 ml/kg by SC, IP, and 
esophageal (PO) injections. 
The ICV administration was performed under ether anaes- 
thesia using isotonic saline as solvent, according to the method 
described by Haley and McCormick (11). Briefly, during an- 
aesthesia, mice were grasped firmly by the loose skin behind 
the head. A 0.4-mm external diameter, hypodermic needle 
attached to a lo-p1 syringe was inserted perpendicularly 
through the skull with no more than 2 mm into the brain of 
the mouse, where 5 ~1 was then administered. The injection 
site was 1 mm on the right or on the left from the midline 
along a line drawn through to the anterior base of the ears. 
Injection was performed into the right or into the left ventricle 
randomly. To ascertain that the drugs were administered ex- 
actly into the cerebral ventricle, some mice were injected with 
5 ~1 of diluited 1 : 10 Indian ink and their brains examined 
macroscopically after sectioning. 
Statistical Analysis 
Results are given as the mean + SEM; ANOVA test was 
used to verify significance between two means. Values of p 
< 0.05 were considered significant. Data were analyzed with 
computer program (StatView for the Macintosh, 1992). 
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TABLE 1 
EFFECT OF PIRACETAM ON BACLOFEN-, BICUCULLINE; AND PICROTOXIN-INDUCED ANTINOCICEPTION 
IN THE MOUSE HOT PLATE TEST (52.5-Z) 
Licking Latency in Mice (s) 
Pretreatment Treatment 




Treatment 15 min 
After Treatment 





































25 15.0 + 0.7 
8 15.6 k 0.8 
8 13.4 f 0.6 
9 14.4 + 0.8 
10 15.2 + 0.8 
8 14.7 + 0.9 
15 15.4 f 0.5 
25 14.4 + 0.5 
17 15.1 f 0.6 
7 14.0 + 0.6 
17 15.0 + 0.6 
20 14.2 r 0.5 
12 14.4 + 0.8 
15 13.8 + 0.4 
14 13.9 f 0.6 
14 13.7 f 0.6 
13 14.8 -t 0.7 
13 15.4 i 0.7 
14.0 * 0.7 14.4 f 0.8 14.8 k 0.7 14.0 + 0.6 
14.4 * 1.1 15.2 f 0.9 16.0 f 0.9 14.0 + 0.6 
15.2 f 0.7 16.4 XL 1.0 15.0 rt 1.0 14.9 f 0.9 
16.1 k 0.7 14.7 f 0.9 14.3 + 1.0 15.4 + 0.9 
15.0 f 1.8 13.8 + 1.4 13.0 * 1.0 15.6 + 1.4 
14.2 + 0.4 11.9 + 0.7 13.5 * 1.0 12.4 + 1.0 
14.6 f 1.2 13.7 + 1.1 14.5 f 1.1 15.7 + 1.2 
24.4 f 1.8 33.4 * 1.9 30.4 f 2.2 26.9 + 2.2 
22.8 f 1.3 29.7 f 2.2 28.8 f 1.6 24.6 k 2.1 
24.0 f 2.6 22.7 f 3.6* 26.6 + 4.1 22.8 + 2.7 
20.4 t 2.4 23.4 k 2.07 28.0 + 2.1 24.5 ik 2.6 
18.9 + 1.4, 24.4 k 2.Ot 34.1 i 2.4 25.5 f 2.6 
14.0 t 0.71 17.2 f 0.8$ 21.2 f 1.8t 23.7 f 2.1 
14.4 t 0.9$ 15.7 k l.l$ 17.3 k 0.8$ 18.1 k 1.11 
39.1 + 2.5 24.6 + 2.2 17.2 rt 2.2 15.3 * 0.9 
24.0 f 2.8$ 15.3 * 1.9t 13.1 + 1.9 11.8 + 1.1 
33.9 f 2.4 30.3 + 3.0 17.5 * 1.2 13.8 f 0.7 
22.0 f 2.2t 20.8 f 2.4* 15.2 + 1.0 14.8 + 0.8 
Piracetam was administered I5 min before bicuculline and simultaneously injected with baclofen and picrotoxin. 
*p < 0.05, tp < 0.01, $p < 0.001 vs. saline/corresponding analgesic drug-treated mice. 
TABLE 2 
EFFECT OF ANIRACETAM ON BACLOFEN-, BICUCULLINE-, AND PICROTOXIN-INDUCED ANTINOCICEPTION 
IN THE MOUSE HOT PLATE TEST (52.5’(Z) 
Licking Latency in Mice (s) 
Pretreatment Treatment Number 
(mg/kg, PO) (mg/kg. SC) of Mice 
CMC saline 19 
Aniracetam 1 saline 8 
Aniracetam 3 saline 8 
Aniracetam 10 saline 8 
Aniracetam 30 saline IO 
Aniracetam 100 saline 8 










baclofen 4 10 
baclofen 4 8 
baclofen 4 10 
baclofen 4 14 
baclofen 4 11 
bicuculline 1.5 8 
bicuculhne 1.5 16 
picrotoxin 1 9 
picrotoxin 1 10 
Before 
Treatment 
14.1 + 0.4 
15.2 + 0.7 
14.1 + 0.8 
15.1 + 0.5 
13.5 + 0.7 
15.2 i 0.7 
14.1 -t 0.5 
14.8 f 0.6 
13.0 f 0.7 
14.1 * 0.7 
14.1 + 0.5 
13.3 + 0.4 
13.4 + 0.7 
13.9 + 0.4 
15.5 & 1.0 
13.4 + 0.6 
After Treatment 
15 min 30 min 45 min 60 min 
14.5 + 0.6 14.4 + 0.6 14.1 + 0.4 15.0 f 0.6 
14.4 _t 0.7 14.2 f 0.9 16.5 t 1.1 14.2 + 0.7 
14.3 + 0.9 14.1 * 1.1 15.6 f 1.3 14.7 f 1.2 
15.7 + 0.8 16.4 of: 0.7 16.6 + 0.9 16.2 f 1.2 
13.1 c 1.2 14.6 + 0.5 12.4 + 0.9 13.6 + 0.6 
15.9 t 0.6 15.1 f 0.5 16.4 + 0.8 17.0 f 0.8 
32.3 k 2.2 37.6 + 2.2 32.9 rt 2.4 28.8 + 2.6 
20.6 zk 2.0$ 24.8 + 2.7t 27.0 5 2.9 26.7 f 3.3 
20.4 + 1.3$ 23.2 zk 2.Ot 24.0 + 2.2 21.0 f 1.9 
21.4 k 1.3$ 30.3 + 2.4* 25.8 f 2.7 22.8 + 2.2 
22.9 + 2.Ot 28.0 + 3.0* 27.3 + 2.5 27.6 k 3.0 
14.1 + 1.81 20.3 LIZ 1.8$ 17.4 * 1.5$ 16.9 k 0.8$ 
42.4 + 1.9 29.0 f 2.1 14.6 + 1.0 15.6 rt 1.1 
29.9 + 1.9$ 22.7 f 1.7* 17.0 + 0.7 16.3 f 0.9 
32.4 -I 2.9 31.9 + 3.7 17.4 + 2.0 15.4 + 0.9 
25.1 f 2.6t 19.4 + 2.4; 17.6 rt 1.4 18.7 + 1.6 
Aniracetam was administered 30 min before bicuculline and 15 min before baclofen and picrotoxin. 
*p < 0.05, tp < 0.01, $p < 0.001 vs. mice treated with carboxymethylcellulose (CMC)/corresponding analgesic drug. 
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Effect of Piracetam and Aniracetam on Antinociception 
Induced by Direct and Indirect GABAH Receptor Activation 
As shown in Tables 1 and 2 and in Fig. 2, piracetam (l-300 
mg/kg, IP, and 10 pg per mouse, ICV), and aniracetam (l- 
100 mg/kg, PO) did not modify the pain threshold in the 
mouse hot plate test. Similarly, piracetam (30 mg/kg, IP) and 
aniracetam (10 mg/kg, PO) did not modify the number of 
abdominal constrictions in the mouse writhing test (Fig. 3). 
Piracetam, starting from 5 mg/kg up to 100 mg/kg, re- 
duced baclofen analgesia in a dose-dependent manner. The 
dose of 100 mg/kg was able to completely prevent this effect 
up to 30 min after administration, whereas the dose of 300 
mg/kg exerted its antagonism at all times that it was tested 
(Table 1). 
Subconvulsant doses of bicuculline (1.5 mg/kg, SC) and 
picrotoxin (1 mg/kg, SC) showed analgesic properties with an 
efficacy similar to that of baclofen. Their latency and duration 
of action, however, were shorter than those of baclofen whose 
antinociceptive action reaches its maximum after 30 min and 
persists up to 60 min. Bicuculline and picrotoxin reached their 
maximum effect 15 min after administration and the antinoci- 
ceptive effect completely disappeared after 45 min. Piracetam 
(30 mg/kg, IP), administered simultaneously with picrotoxin 
and 15 min before bicuculline, showed the capability to pre- 
vent the increase of pain threshold at both 15 and 30 min 
after analgesic drugs administration (Table 1). A statistically 
significant reduction of baclofen antinociception was also ob- 
tained with aniracetam, at doses ranging between 1 and 30 
mg/kg, whereas a full antagonism was reached when 100 
mg/kg PO of aniracetam were administered. Aniracetam, more- 
over, reduced bicuculline and picrotoxin analgesia when admin- 
Q saline 10 ml kg-’ 5.~. + saline 5 ~1 prr mouse I c v (4) 
-+ saline 10 ml kg’ S.C. + piracetam 10 pg per mouse I c Y (6) 
+- baclofen 4 mg kg’ 5 c + saline 5 ~1 I c v (12) 
+ baclofen 4 mg kg-’ s c. + pnacetam 5 fig per mouse I c Y (12) 
-+ baclofen 4 mg kg-’ S.C. + pxacetam 10 wg per ~OUSC 1 c v (12) 
FIG. 2. Effect of piracetam on baclofen-induced analgesia after ICV 
administration. Piracetam was injected 5 min before analgesic treat- 
ment. Vertical lines give SEM; the number of mice is shown in paren- 
theses. *P < 0.05 compared with baclofen-treated mice. 
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t.lCi. 3. Effect of (a) piracetam and (b) aniracetam on baclofen-, 
picrotoxin-, and bicuculline-induced antinociception in the mouse ace- 
tic acid abdominal constriction test. Piracetam was simultaneously 
administered with baclofen and picrotoxin whereas bicuculline was 
injected I5 min after piracetam. Aniracetam was administered 15 min 
before picrotoxin and baclofen. Bicuculline was injected 30 min after 
aniracetam. The number of writhes was counted between 15 and 25 
min after bicuculline and between 30 and 40 min after baclofen and 
picrotoxin administration. Vertical lines represent SEM; the number 
of mice is shown in parentheses. *p < 0.001 vs. corresponding anal- 
gesic drug-treated mice. 
istered at the dose of 10 mg/kg PO 30 and 15 min, respectively, 
before the two analgesic compounds (Table 2). ICV injection of 
piracetam at the dose of 1 pg per mouse did not antagonize 
baclofen-induced antinociception whereas 10 pg per mouse sig- 
nificantly reduced it (Fig. 2). 
The effect of piracetam and aniracetam on antinociception 
induced by baclofen, bicuculline, and picrotoxin was also 
tested using the abdominal constriction test in mice. Both noo- 
tropic drugs were able to antagonize the analgesic effect pro- 
duced by SC injection of all three analgesic compounds, as 
illustrated in Fig. 3. 
Effect of Piracetam, Aniracetam, and CGP 35348 on Pain 
Threshold Increased by non-GABAergic Drugs 
Piracetam, up to the dose of 30 mg/kg IP, did not modify 
the enhanced paw licking latency in the mouse hot plate 
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test induced by analgesic compounds such as morphine (7 
mg/kg, SC), physostigmine (0.2 mg/kg, SC), clomipramine 
(25 mg/kg, SC), and diphenhydramine (20 mg/kg, SC), which 
are considered as nonacting through the GABA system. How- 
ever, the dose of 50 mg/kg IP antagonized morphine-induced 
antinociception and diminished the clomipramine analgesic 
effect. The enhanced pain threshold induced by physostigmine 
and diphenhydramine was significantly reduced only when 
piracetam was given at the dose of 100 mg/kg IP (Table 3). 
Aniracetam, at the doses of 10 and 30 mg/kg PO, was unef- 
fective in modifying non-GABAergic analgesia. The dose of 
100 mg/kg PO showed the capability of preventing clomi- 
pramine- and diphenhydramine-induced antinociception, but 
did not affect morphine and physostigmine analgesic effect 
(Table 3). 
Figure 4 shows the results obtained with the abdominal 
constriction test in mice showing the piracetam and anira- 
cetam uneffectiveness in preventing morphine (1 mg/kg, SC), 
physostigmine (0.2 mg/kg, SC), clomipramine (25 mg/kg, 
SC), and diphenhydramine (20 mg/kg, SC) induced analgesia 
at the doses used (10 and 100 mg/kg). 
The increased paw licking latency due to the above- 
mentioned analgesic drugs was not affected by pretreat- 
ing mice with CGP 35348 up to the dose of 0.5 pg per 
mouse ICV, as reported in Table 4. A progressive increase 
of the dose of CGP 35348 (from 0.5 to 5 pg per mouse) pre- 
vented antinociception induced by non-GABAergic drugs 
in the following order: diphenhydramine, clomipramine, 
physostigmine, and morphine. Table 4 shows that CGP 35348, 
at the dose of 0.5 pg per mouse, was able to reduce diphen- 
hydramine (20 mg/kg, SC) analgesia. At the dose of 2.5 pg 
per mouse, CGP 35348 completely prevented diphenhy- 
dramine effect and also reduced the enhanced pain threshold 
induced by clomipramine (25 mg/kg, SC) administration. At 
higher doses (5 pg per mouse), CGP 35348 completely antago- 
nized physostigmine (0.2 mg/kg) analgesic effect and signifi- 
cantly prevented morphine-induced (7 mg/kg) antinocicep- 
tion. 
TABLE 3 
EFFECT OF PIRACETAM AND ANIRACETAM ON DIPHENHYDRAMINE-, CLOMIPRAMINE, 
PHYSOSTIGMINE-. AND MORPHINE-INDUCED ANTINOCICEPTION IN THE MOUSE 
HOT PLATE TEST (52.5“C) 







” Treatment I5 min 30 min 
Saline IP 
Saline IP 
Piracetam 30 IP 
Piracetam 50 IP 
Piracetam 100 IP 
Saline IP 
Piracetam 30 IP 
Piracetam 50 IP 
Saline IP 
Piracetam 30 IP 
Piracetam 50 IP 
Piracetam 100 IP 
Saline IP 
Piracetam 30 IP 
Piracetam 50 IP 
CMC PO 
CMC PO 
Aniracetam 10 PO 
Aniracetam 30 PO 
Aniracetam 100 PO 
CMC PO 
Aniracetam 10 PO 
Aniracetam 30 PO 
Aniracetam 100 PO 
CMC PO 
Aniracetam 10 PO 
Aniracetam 30 PO 
Aniracetam 100 PO 
CMC PO 
Aniracetam 10 PO 
Aniracetam 30 PO 

































25 15.0 i 0.7 14.0 + 0.7 14.4 k 0.8 
12 15.4 it 0.6 24.5 f 1.3 22.2 + 1.4 
12 16.0 * 0.5 22.9 + 1.2 20.5 + 1.2 
13 15.7 * 0.7 25.8 + 1.5 24.8 + 2.0 
13 14.5 f 0.6 20.5 + l.O* 20.1 + 1.1 
10 14.8 * 0.9 22.0 + 1.8 25.0 + 2.3 
10 14.6 + 0.7 20.3 + 2.0 22.9 f 2.4 
10 13.4 f 0.6 19.8 f 1.7 18.0 f 1.3* 
12 14.7 f 0.9 34.0 k 2.3 32.5 + 3.2 
12 13.5 + 0.6 33.2 + 2.7 33.7 f 3.0 
13 15.6 f 0.7 36.5 + 2.3 40.0 + 2.1 
13 13.3 f 0.6 23.5 + 2.8’ 26.5 + 2.8 
13 15.4 + 0.6 26.6 + 1.6 26.9 + 2.2 
10 15.9 + 0.7 25.0 + 2.1 26.6 + 2.5 
IO 13.4 + 0.6 16.0 rt 1.2$ 17.1 + 1.5$ 
10 14.5 + 0.6 15.0 + 0.7 15.2 + 0.8 
10 13.7 + 0.4 25.4 f 1.1 23.6 +z 1.4 
10 14.7 + 0.5 24.8 rt 0.8 22.1 * 0.5 
9 14.4 * 0.7 26.7 + 2.0 24.0 f 1.8 
9 14.3 + 0.6 18.5 + 2.5* 16.4 + I.27 
9 15.5 * 0.5 24.3 + 0.9 32.7 + 1.8 
10 14.6 + 0.7 23.1 + 1.1 32.5 + 2.4 
10 15.9 f 0.7 25.6 + 1.9 31.1 + 2.6 
9 14.4 + 0.7 18.1 f 1.9-f 21.1 + 2.7$ 
12 13.5 + 0.4 34.5 f 2.7 36.3 f 3.1 
13 14.7 + 0.6 31.1 k 3.2 36.4 + 2.6 
9 15.1 + 0.8 38.3 + 2.5 37.4 k 3.2 
10 16.7 f 0.6 36.0 + 2.4 39.0 f 2.0 
12 13.8 i 0.7 28.1 + 3.0 29.8 f 3.1 
12 14.9 + 0.6 29.0 f 2.9 34.3 + 2.7 
12 14.3 + 0.5 22.0 + 2.4 28.6 f 2.6 
10 14.5 f 0.6 27.3 + 1.9 27.8 + 1.8 
*p < 0.05, tp < 0.01, $p < 0.001 vs. corresponding analgesic drug-treated mice. 
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saline phgrostigmine diphenhydramine morphine clomipraminr 
10 ml kg-’ 0.2 mg kK-’ 20 mg kg-’ I mg kg.’ 2.5 mg kg ' 
0 saline IOmlkg- q prace~~m IOrng hg ' q puairwn 111Oq hi: ' 
reline physorllgmine diphenhydromine morphine rlomiprmninu 
10 ml kg-’ 0.2 mg kg ’ 20 mg 4-l Impkg’ 2.5 mp kr.’ 
cl; 
i~rho\vmrtl,~lcell~llose q a"ll‘lCCtdlll i l nil: is •<~"lrdl,~t‘~ill IOIl mx hg 
FIG. 4. Effect of (a) piracetam and (b) aniracetam on physostigmine, 
diphenhydramine, morphine, and clomipramine-induced analgesia in 
the mouse abdominal constriction text. Piracetam (IP), physostigmine 
(SC), morphine (SC), and clomipramine (SC) were administered 30 
min before the test. Diphenhydramine (SC) was administered 15 min 
after piracetam administration. Aniracetam (PO) was administered 15 
min before physostigmine, morphine, and clomipramine. Diphenhy- 
dramine was administered 30 min after aniracetam administration. 
The number of writhes was counted between 30 and 40 min after 
piracetam injection and between 45 and 55 min after aniracetam ad- 
ministration. The number of mice is shown in parentheses. Vertical 
lines represent the SEM. ‘p < 0.05, **p < 0.01 compared with 
clomipramine-treated mice. 
Antagonism by Piracetam and Aniracetam of 
Baclofen-Induced Motor Incoordination 
Baclofen (6 mg/kg, SC) produced impairment of rota-rod 
performance in mice (Fig. 5). The motor incoordination 
reached its maximum 45 min after baclofen administration 
and then this effect was slowly reduced. Piracetam, at the dose 
of 30 mg/kg IP, simultaneously administered with baclofen, 
showed the ability to significantly reduce the impairment of 
rota-rod performance, as shown in Fig. 5. Aniracetam, at 
the dose of 10 mg/kg PO injected 15 min before baclofen, 
completely antagonized the decrease of the endurance time on 
the rotating treadmill (Fig. 5). 
DISC‘USSION 
The results obtained have shown a very similar pharmaco- 
logical behaviour between the effect of CGP 35348 and the 
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two nootropic drugs piracetam and aniracetam. Piracetam 
and aniracetam, like CGP 35348, were able to reduce analge- 
sia mediated via GABA, receptor activation. Such reduction 
was obtained not only on antinociception induced by baclofen 
(a direct GABA, agonist), but also on antinociception induced 
by subconvulsant doses of bicuculline and picrotoxin (indirect 
GABA, agonists). Malcangio et al. (18) have shown that bicu- 
culline and picrotoxin, acting as GABA, antagonists, might 
be able to release GABA and thus induce antinociception. The 
reduction of GABAergic analgesia observed after piracetam, 
aniracetam, and CGP 35348 administration was detected in 
both of the analgesic tests used (hot plate and abdominal con- 
striction). The two nootropic drugs as well as CGP 35348 were 
also able to antagonize morphine, physostigmine, clomipram- 
ine, and diphenhydramine antinociception. However, the an- 
tagonism towards the above mentioned non-GABAergic drugs 
was observed only in the hot plate test. Moreover, doses of 
CGP 35348, piracetam, and aniracetam higher than those able 
to interfere with baclofen, bicuculline, and picrotoxin antino- 
ciception were necessary. No interference with non-GABAergic 
antinociception was observed in the abdominal constriction 
test also following high doses of piracetam and aniracetam. 
Similar results concerning the lack of antagonism in the ab- 
dominal constriction test on non-GABAergic analgesia using 
CGP 35348 have been previously reported (17). In the abdomi- 
nal constriction test, however, piracetam and aniracetam, un- 
like CGP 35348, never were able to completely prevent baclo- 
fen antinociception, showing, therefore, a lower potency than 
CGP 35348. 
The pharmacological analogy among the three compounds 
(piracetam, aniracetam, and CGP 35348) is validated by the 
fact that, in both of the analgesic tests, they were able to 
selectively reduce GABAergic antinociception when adminis- 
tered at the minimal effective doses. At the moment, we do 
not have any convincing explanation about the lack of antago- 
nism in the abdominal constriction test of non-GABAergic 
analgesia by high doses of piracetam, aniracetam, and CGP 
35348. It should be taken into account, however, that the 
abdominal constriction test induces, unlike the hot plate test, 
a prolonged inflammatory pain that activates endogenous 
antinociceptive mechanisms that are different from those in- 
volved in acute pain. 
Piracetam action on analgesia appears centrally mediated 
because it reduced baclofen antinociception also when injected 
ICV. Aniracetam, because of its poor water solubility, was 
not tested after ICV administration and only the oral route of 
administration was used. 
The GABAB antagonist CGP 35348 was found to be able 
to selectively prevent baclofen-induced motor incoordination 
(17). A similar effect has now also been obtained with pira- 
cetam and aniracetam, which respectively reduced and com- 
pletely antagonized the impairment of rota-rod performance 
induced by baclofen administration, without modifying the 
endurance time on the rota-rod treadmill when given alone. 
Therefore, because the two nootropic drugs, like CGP 35348, 
were able to selectively antagonize both baclofen-induced mo- 
tor incoordination and analgesia, we could hypothesize that 
the nootropic activity of piracetam and aniracetam might be 
due to a reduction of the inhibitory effects of endogenous 
GABA. Piracetam and aniracetam might, therefore, interfere 
either directly with GABA, receptors sharing the same mecha- 
nism as CGP 35348, or indirectly with some other GABA, 
postreceptorial events. 
Binding studies have demonstrated that only high pira- 
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TABLE 4 
EFFECT OF CGP 35348 ON DIPHENHYDRAMINE-, CLOMIPRAMINE-, PHYSOSTIGMINE-, AND 
MORPHINE-INDUCED ANTINOCICEPTION IN THE MOUSE HOT PLATE TEST (52.S°C) 
Licking Latency in Mice (s) 
After Treatment 
Pretreatment Treatment Number Before 
(pg per Mouse, ICV) (mdkg, SC) of Mice Treatment 15 min 30 min 
Saline saline 10 14.8 t 0.9 13.4 f 0.7 14.8 zt 1.3 
CGP-35348 5 saline 10 13.5 t 0.7 13.1 + 1.2 14.6 zt 0.5 
Saline diphenhydramine 20 10 15.8 + 0.6 24.0 f 1.0 24.1 + 0.7 
CGP-35348 0.5 diphenhydramine 20 11 15.4 f 1.0 19.5 f 1.7* 24.0 + 1.6 
CGP-35348 2.5 diphenhydramine 20 7 14.0 f 0.9 17.7 + 1.8$ 14.7 + 1.3$ 
Saline clomipramine 25 7 16.8 f 0.9 20.1 + 0.7 23.0 + 1.5 
CGP-35348 0.5 clomipramine 25 10 14.6 i 0.6 17.6 + 1.1 21.6 of: 0.9 
CGP-35348 2.5 clomipramine 25 IO 15.3 * 0.7 15.5 * 1.2t 17.3 * 1.ot 
Saline physostigmine 0.2 8 15.5 f 0.8 37.2 + 3.8 37.6 + 1.9 
CGP-35348 2.5 physostigmine 0.2 8 16.0 f 0.9 38.7 + 2.3 39.8 k 2.0 
CGP-35348 5 physostigmine 0.2 13 15.1 + 0.8 16.8 + 1.9$ 16.3 + 1.9$ 
Saline morphine 7 9 14.9 + 0.8 35.0 + 3.1 37.8 f 2.4 
CGP-35348 5 morphine 7 14 13.6 k 1.1 20.3 + 1.9$ 20.6 f 2.87 
All pretreatment drugs were administered 5min before treatment injection. 
*p c 0.05, tp < 0.01, $p < 0.001 vs. saline/corresponding analgesic drug-treated mice. 
cetam and aniracetam concentrations (IC,, ranging between 
0.2 and 50 mM) inhibited GABA, GABA,, opiate, serotonin, 
and benzodiazepine receptor binding sites in the central ner- 
vous system (1,22). Such concentrations were much higher 
FIG. 5. Effect of piracetam and aniracetam on baclofen-induced im- 
pairment of rota-rod performance in the mouse rota-rod test. Pira- 
cetam was simultaneously injected with baclofen while aniracetam 
was administered 15 min before baclofen. Endurance time of mice on 
the treadmill was recorded before treatment and then starting 15 min 
after baclofen treatment up to 75 min. The number of mice ranging 
was between 8 and 16. Vertical lines represent SEM. *p < 0.05, **p 
< 0.01, ***p < 0.001 vs. baclofen-treated mice. 
than those able to exert a nootropic effect in vivo; therefore, 
in spite of the fact that piracetam and aniracetam are cyclic 
derivatives of GABA, their action cannot be explained by a 
direct GABA receptor antagonism. In fact, although no litera- 
ture on the affinity of piracetam and aniracetam for GABA, 
receptor is available, the very high concentrations necessary to 
inhibit GABA binding seem to exclude, for these two drugs, 
an action mechanism similar to that described for CGP 35348 
that directly blocks GABA, receptors. Because the inhibitory 
activity of GABAB receptors is mediated by pertussis toxin- 
sensitive G-proteins (9,15) and baclofen-induced antinocicep- 
tion is prevented by pretreatment with pertussis toxin (14), we 
can hypothesize an interference of 2-pyrrolidinone com- 
pounds directly on G-proteins or on G-protein-mediated ef- 
fects. 
An interaction of piracetam and aniracetam metabolites 
with GABA receptors seems very unlikely. It has been re- 
ported, in fact, that piracetam is excreted pratically un- 
changed in the urine (10). Moreover, although aniracetam is 
transformed in vivo to amide and acid (lo), there is no evi- 
dence of a possible interaction of these metabolites with 
GABA receptors. 
We can exclude that the antagonism of baclofen analgesia 
produced by piracetam and aniracetam may be due to some 
behavioral side effects elicited by these two drugs. At all doses 
used of piracetam and aniracetam, the normal behavior of 
mice appeared on observation to be wholly comparable to that 
of the controls and the animals did not exhibit any impairment 
on the rota-rod test. 
Because it is necessary for the reversal of cognitive impair- 
ment to use doses of the three nootropic drugs that are higher 
than those we found selective for GABAergic analgesia, we 
cannot exclude that the nootropic effect might be mediated by 
inhibition not only of GABAergic system, but also of other 
inhibitory mechanisms uch as those involved in opioid, cho- 
linergic, and serotoninergic analgesias. To ameliorate cogni- 
tive impairment in mice it is, in fact, necessary to use doses 
950 GALEOTTI, GHELARDINI AND BARTOLINI 
equal to or higher than 30 mg/kg IP for piracetam (8), IO 
mg/kg PO for aniracetam (6), and 75 mg/kg IP for CGP- 
35348 (2). There are no data regarding the nootropic effect of 
CGP 35348 after ICV administration, but it has been pre- 
viously reported that the dose of 100 mg/kg IP is approxi- 
mately corresponding to 2.5 pg per mouse ICV (17). By using 
these nootropic doses, we obtained a complete block of the 
baclofen antinociception in the hot plate test as well as a re- 
duction of non-GABAergic antinociception. 
In conclusion, these findings may suggest a GABA, recep- 


















tropic effect. This is supported by the fact that, like GABA, 
antagonists, they can prevent baclofen-induced antinocicep- 
tion and muscle relaxation as well as improve learning in mice. 
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